Research progress in radionuclide drug conjugates and considerations on its technology evaluation
With the development of nuclear medicine,nuclear technology and molecular biology,radioligand therapy has become an important development direction of precision medicine.In China,radioligand therapy drugs are usually called radionuclide drug conjugates(RDC).These drugs deliver radionuclides to specific tumor sites by coupling targeted ligand molecules to realize different functions of diagnosis or treatment.This article analyzes the research progress of RDC and the issues faced at the level of technical evaluation,and puts forward relevant reflections and research paths,aiming to provide reference for China's drug regulatory authorities to formulate corresponding policies and measures.
radioligand therapyradionuclide drug conjugatesR&D
NETL
NSTL
万方数据
